Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
EL

NASDAQ · ELDN

Eledon Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.65

Down-$0.02 (-0.75%)

Updated Sep 18, 2026, 6:38 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
102.42M
P/E ratio
-1.65
Dividend yield
0.00%
52-week range
$2.64 – $4.49
Volume
558.4K
Avg. volume
2.2M

Price performance

ELDN price history

1M range · 20 trading sessions · Daily adjusted prices

ELDN closed at $2.65 after 20 trading sessions, down 24.72% for the selected period.

Last close
$2.65
Period change
-24.72%
Period low
$2.65
Period high
$3.52
Daily close
View OHLC price history
ELDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 17, 2026$2.73$2.79$2.615$2.65558.4K
Sep 16, 2026$2.71$2.724$2.64$2.67738.77K
Sep 15, 2026$2.79$2.81$2.655$2.71806.31K
Sep 14, 2026$2.88$2.88$2.75$2.77520.78K
Sep 11, 2026$2.82$2.86$2.75$2.78638.4K
Sep 10, 2026$2.78$2.805$2.75$2.78748.13K
Sep 9, 2026$2.95$2.99$2.81$2.82670.45K
Sep 8, 2026$3.02$3.03$2.91$2.931.02M
Sep 4, 2026$2.975$3.055$2.93$3.021.2M
Sep 3, 2026$3.07$3.10$2.92$2.931.15M
Sep 2, 2026$3.04$3.13$2.92$2.991.22M
Sep 1, 2026$2.93$3.03$2.885$3.011.3M
Aug 31, 2026$3.175$3.175$2.925$2.981.84M
Aug 28, 2026$3.29$3.32$3.17$3.201.02M
Aug 27, 2026$3.36$3.42$3.245$3.32971.18K
Aug 26, 2026$3.47$3.5029$3.335$3.35820.43K
Aug 25, 2026$3.45$3.50$3.40$3.47970.54K
Aug 24, 2026$3.43$3.43$3.265$3.411.14M
Aug 21, 2026$3.54$3.58$3.41$3.45743.92K
Aug 20, 2026$3.53$3.5935$3.42$3.52576.8K

Latest ELDN news

The latest Smart Investors Daily articles mentioning ELDN.

Stock researchCompany · Overview

ELDN research

Overview

Company profile and research snapshot.

Company profile

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ELDN recent ratings
DateFirmRatingTarget
Jul 21, 2026Rodman & RenshawBuy—
Nov 18, 2025GuggenheimBuy—
Sep 2, 2025HC Wainwright & Co.Buy—
Jul 25, 2025Craig-HallumBuy—
Nov 20, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026. Details of the presentation are below: Oral Presentation Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evalua

Yahoo · Sep 3, 2026

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compa

Benzinga · Aug 13, 2026

Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate

Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By